The global biological safety testing products and services market size is expected to reach USD 9.30 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is predominantly driven by the increasing production of biologics, boosting the demand for highly effective biological safety testing tools. The increasing disease burden is expected to be a major factor responsible for the rising production of biologics, thereby propelling the market growth.
The increasing prevalence of chronic diseases associated with lifestyle, including diabetes and cancer, is a key factor contributing to the rise in drug development and subsequent commercialization. This is expected to increase the need for ensuring & scrutinizing the safety of specialized and targeted therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, biotechnology and pharmaceutical companies are increasingly integrating biological safety testing products and services to produce contamination-free and highly potent biologics to cater to the large number of people suffering from target diseases. Safety testing for viral conditions is proving to be one of the primary concerns of most companies as it is a critical component of manufacturing, chemistry, and control of biologics. This is fueling growth opportunities in the market.
Laboratory-based contamination is leading to the development and refinement of workstations by incorporating biological safety products and services. The increasing need to work with tissue cultures, maintain the sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising involvement by government healthcare organizations for implementing good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.
Furthermore, key players operating in the biological safety testing product & services market are constantly focusing on developing novel products and technologies, further expanding their product portfolio, and to meet the rising demand for biological safety testing globally. For instance, in December 2022, -Charles River Laboratories International, Inc. announced the launch of Endosafe Nexus 200, a fully robotic instrument capable of processing both complex or undiluted, serial dilutions for water, in-process, and final product testing, further expanding its endotoxin testing portfolio. The incorporation of automation through robotics has enabled streamlining the quality control process and subsequently improving overall process efficiency.
Biological Safety Testing Products And Services Market Report Highlights
Detail Analysis of Biological Safety Testing Products And Services Market
Biological Safety Testing Products And Services Market Segmentation
Grand View Research has segmented the global biological safety testing products and services market on the basis of product, application, test type, and region:
Biological Safety Testing Products And Services Product Outlook (Revenue, USD Million, 2018 - 2030)
Biological Safety Testing Products And Services Application Outlook (Revenue, USD Million, 2018 - 2030)
Biological Safety Testing Products And Services Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Biological Safety Testing Products And Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
Key Players in the Biological Safety Testing Products And Services Market
Order a free sample PDF of the Biological Safety Testing Products And Services Market Intelligence Study, published by Grand View Research.
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.